protein/mf59
Small moleculeexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02997969)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- protein/mf59
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02997969 | Phase 1 | May 1, 2016 | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), Novartis, University of Lausanne, University of North Carolina at Chapel Hill |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HIV Vaccine Trials Network | Academic/Hospital | 1 | 0 | 1 | 2016 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2016 |
| Novartis | For profit | 1 | 0 | 1 | 2016 |
| University of Lausanne | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2016 |
5 organizations
Page 1 / 1